TR200000756T2 - Davranış bozukluğu tedavisi. - Google Patents

Davranış bozukluğu tedavisi.

Info

Publication number
TR200000756T2
TR200000756T2 TR2000/00756T TR200000756T TR200000756T2 TR 200000756 T2 TR200000756 T2 TR 200000756T2 TR 2000/00756 T TR2000/00756 T TR 2000/00756T TR 200000756 T TR200000756 T TR 200000756T TR 200000756 T2 TR200000756 T2 TR 200000756T2
Authority
TR
Turkey
Prior art keywords
treatment
behavioral disorder
behavioral
disorder
reuptake inhibitors
Prior art date
Application number
TR2000/00756T
Other languages
English (en)
Inventor
Harrison Heiligenstein John
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200000756T2 publication Critical patent/TR200000756T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Norepinefrini geri alma inhibitörleri davranis bozuklugunun tedavisinde kullanilmaktadirlar.
TR2000/00756T 1997-09-23 1998-09-01 Davranış bozukluğu tedavisi. TR200000756T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5962897P 1997-09-23 1997-09-23

Publications (1)

Publication Number Publication Date
TR200000756T2 true TR200000756T2 (tr) 2000-09-21

Family

ID=22024194

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00756T TR200000756T2 (tr) 1997-09-23 1998-09-01 Davranış bozukluğu tedavisi.

Country Status (17)

Country Link
US (1) US6184222B1 (tr)
EP (1) EP0919235A1 (tr)
JP (1) JP2001517619A (tr)
KR (1) KR20010024219A (tr)
CN (2) CN1271278A (tr)
AU (1) AU740192B2 (tr)
BR (1) BR9812371A (tr)
CA (1) CA2304657C (tr)
EA (1) EA002804B1 (tr)
HU (1) HUP0004025A3 (tr)
IL (1) IL134718A0 (tr)
NO (1) NO20001479D0 (tr)
NZ (1) NZ502853A (tr)
PL (1) PL339425A1 (tr)
TR (1) TR200000756T2 (tr)
UA (1) UA57107C2 (tr)
WO (1) WO1999015163A1 (tr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512965A (ja) * 1998-04-24 2002-05-08 スカリスタ リミティッド 鬱病の治療およびそのための薬学的調製物
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
AU2005220235B2 (en) * 1999-07-01 2007-05-10 Pharmacia & Upjohn Company Selective norepinephrine reuptake inhibitors and methods of using the same
ATE305788T1 (de) 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc (s,s)-reboxetin zur behandlung von inkontinenz
SI1196172T1 (sl) * 1999-07-01 2006-06-30 Pharmacia & Upjohn Co Llc (S,S)-reboksetin za zdravljenje kronicne bolecine
US6387403B1 (en) * 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
ATE519485T1 (de) * 2001-03-29 2011-08-15 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
US6613763B2 (en) * 2001-04-20 2003-09-02 Mgi Applied Genomics Use of molindone to treat oppositional defiant disorder and conduct disorder
CA2752782A1 (en) * 2001-07-11 2003-01-23 Cns Response, Inc. Electroencephalography based systems and methods for selecting therapies and predicting outcomes
US6700018B2 (en) * 2001-07-17 2004-03-02 Mayo Foundation For Medical Education And Research Amine compounds and inhibiting neurotransmitter reuptake
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
WO2003068211A1 (en) * 2002-02-12 2003-08-21 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
PT1485078E (pt) * 2002-03-15 2013-01-14 Cypress Bioscience Inc Milnacipran para o tratamento do síndrome do intestino irritável
BR0309259A (pt) * 2002-04-18 2005-02-09 Pharmacia Corp Terapia combinada para o tratamento de doença de parkinson com inibidores de ciclooxigenase-2 (cox 2)
PL375211A1 (en) * 2002-06-17 2005-11-28 Pharmacia Italia S.P.A. Pharmaceutical salts of reboxetine
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US6943193B1 (en) * 2003-01-21 2005-09-13 Jordan A. Altabet Method for treating sexual dysfunction
NZ541733A (en) * 2003-02-14 2009-03-31 Pf Medicament Use of the enantiomer (1S,2R) of milnacipran for the preparation of a medicament
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
US20070032554A1 (en) * 2003-08-27 2007-02-08 Elililly And Company A Corporation Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
ES2390879T3 (es) * 2003-12-31 2012-11-19 Actavis Group Ptc Ehf. Formulaciones de atomoxetina
EP1791806A4 (en) * 2004-06-07 2008-02-20 Mayo Foundation AMINE COMPOUNDS AND NEUROTRANSMITTER RECOVERY INHIBITION
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080031932A1 (en) * 2006-08-04 2008-02-07 Watson Laboratories, Inc. Transdermal atomoxetine formulations and associated methods
WO2009089479A2 (en) 2008-01-09 2009-07-16 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
JP2013510176A (ja) 2009-11-06 2013-03-21 ピエール ファーブル メディカモン （１ｓ，２ｒ）−２−（アミノメチル）−ｎ，ｎ−ジエチル−１−フェニルシクロプロパンカルボキサミドの新規結晶形態
US9944618B2 (en) 2013-03-14 2018-04-17 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
RU2669280C2 (ru) * 2013-04-30 2018-10-09 ЭйДжиСи Инк. Композиция, содержащая трифторэтилен

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA921292B (en) * 1991-02-25 1993-08-23 Lilly Co Eli Treatment of lower urinary tract disorders.
DK0537915T3 (da) * 1991-09-27 1995-11-27 Lilly Co Eli N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
ZA93694B (en) * 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
IL122984A0 (en) * 1995-07-24 1998-08-16 Lilly Co Eli Treatment of attention-deficit/ hyperactivity disorder
US5696168A (en) * 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder

Also Published As

Publication number Publication date
PL339425A1 (en) 2000-12-18
AU740192B2 (en) 2001-11-01
NO20001479L (no) 2000-03-22
US6184222B1 (en) 2001-02-06
CA2304657A1 (en) 1999-04-01
JP2001517619A (ja) 2001-10-09
NO20001479D0 (no) 2000-03-22
EA200000351A1 (ru) 2000-10-30
CA2304657C (en) 2005-10-25
UA57107C2 (uk) 2003-06-16
IL134718A0 (en) 2001-04-30
BR9812371A (pt) 2000-09-19
CN1762338A (zh) 2006-04-26
CN1271278A (zh) 2000-10-25
HUP0004025A2 (hu) 2002-01-28
NZ502853A (en) 2002-08-28
EP0919235A1 (en) 1999-06-02
AU9041798A (en) 1999-04-12
WO1999015163A1 (en) 1999-04-01
KR20010024219A (ko) 2001-03-26
HUP0004025A3 (en) 2002-02-28
EA002804B1 (ru) 2002-10-31

Similar Documents

Publication Publication Date Title
ES2182906T3 (es) Grapa quirurgica helicoidal.
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
TR200000374T2 (tr) Akut akciğer harabiyeti ve fibrozitinin alfavbeta6 antagonistleriyle tedavisi.
DZ2026A1 (fr) Compositions vaccinantes.
DZ2055A1 (fr) Compositions vaccinantes.
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
TR199801255T2 (tr) Vitronektin reseptör antagonistleri.
TR199501472A2 (tr) Matriks metaloproteaz inhibitörler.
EA200000351A1 (ru) Лечение кондуктивных нарушений
SE9904377D0 (sv) Pharmaceutical combinations
ATE254917T1 (de) Mittel gegen parasitäre protozoen
TR199600371A2 (tr) Organosilan bilesiklerinin harmanlari ve bunlarin kullanimi.
DE69625230D1 (de) Thrombininhibitoren
PT888330E (pt) Metodos de tratamento ou prevencao de cistite intersticial
BG100248A (bg) Инхибитори на скваленсинтетаза
FR2716375B3 (fr) Injecteur médical.
ATE215084T1 (de) Imidazopyridin-azolidinone
MX9909797A (es) Composiciones para el cuidado personal que comprenden un copolimero adhesivo.
NO20005548L (no) Mykobakterieinhibitorer
FR2721211B1 (fr) Gel gommant huileux.
EP0764204A4 (en) HUMANE OXALYL-CoA DECARBOXYLASE
PT1052991E (pt) Utilizacao de loperamida para o tratamento de infeccoes microbianas
BR9801839A (pt) Medicamento analgésico e aplicação de (+) -0-demetiltramadol.